This website is intended for Ireland Healthcare Professionals only. Not a Healthcare Professional in Ireland? Click here
BETMIGA™ (mirabegron) logo

Betmiga™ (mirabegron) is indicated for symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome and for treatment of neurogenic detrusor overactivity (NDO) in paediatric patients aged 3 to <18 years.1

OAB has a substantial impact on patients’ daily lives
OAB has a substantial impact on patients’ daily lives
Work

Work

OAB symptoms can affect concentration and negatively impact work activity2-3

Sleep

Sleep

OAB symptoms can disrupt sleep3-4

Social life

Social life

OAB symptoms can restrict social activities3-4

Patients often need to plan ahead or avoid social activities altogether, leading to isolation and lower QoL5-7

OAB, overactive bladder; QoL, Quality of Life.

Ask your patients are they experiencing any of these OAB symptoms:8-10

URGENCY: KEY SYMPTOM
  • URGENCY KEY SYMPTOM

Sudden, compelling desire to urinate which is difficult to put off

Frequency
  • FREQUENCY

Voiding too often during their waking hours

nocturia
  • NOCTURIA

Waking up at night more than once to void

NOT ALWAY PRESENT
  • URGENCY INCONTINENCE NOT ALWAY PRESENT

Involuntary leakage of urine, accompanied by or immediately preceded by urgency

BETMIGA demonstrated improvements in key QoL outcomes vs placebo11,12

In SCORPIO, a 12-week Phase III trial (n=1978) assessing the efficacy and safety of BETMIGA in men and women aged ≥18 years with OAB symptoms ≥3 months11

Patients showed greater improvements in rates of:*

Symptom bother

Symptom bother

32% better than placebo

Patient perception

Patient perception

25% better than placebo

Treatment satisfaction

Treatment satisfaction

35% better than placebo

*Mean change from baseline (change from baseline to final visit): 32% in symptom bother (-14.9 vs -19.6, p<0.001); 25% in patient perception (-0.8 vs -1.0, p=0.045) and 35% in treatment satisfaction (1.89 vs 2.55, p=0.001).11

In BELIEVE, a 12-month non-interventional study in patients (n=796) prescribed BETMIGA, clinically meaningful changes in QoL from baseline vs placebo were observed at 10–12 months12

Patients reported meaningful improvements in (FAS):*

Coping

Coping

47% of patients improved

Concern

Concern

47% of patients improved

Sleep

Sleep

44% of patients improved

*Patients achieving ≥10 point improvement in the coping, concern and sleep subscales of the OAB-q.12 Meaningful improvements were reported in 47% of patients for coping (mean change 20.1), 47% of patients for concern (mean change 19.4) and 44% of patients for sleep (mean change 17.5).12

FAS, full analysis set; OAB, overactive bladder; OAB-q, Overactive Bladder Questionnaire; QoL, quality of life.

References

1. BETMIGA (mirabegron) prolonged-release tablets. Summary of Product Characteristics; 2. Milsom I. BJOG. 113:2–8. doi: 10.1111/j.1471-0528.2006.01081.x; 3. Tubaro A. Urology. 2004;64(6 Suppl 1):2–6; 4. Coyne KS et al, Neurourol Urodyn. 2009;28:969–975; 5. Nicolson P, et al. 2008;13(Pt 2):343–359; 6. Ricci JA, et al. Clin Ther. 2001;23(8):1245–1259; 7. Scrivens, R. Nursing Times. 2022;118(6):34–37; 8. International Continence Society. Overactive bladder. Available from: https://www.ics.org/public/factsheets/overactivebladder 9. Haylen, BT. et al. Int. Urogyn. Journal. 2010; 21: 5-26. 10. Abrams P. Urology. 2003; 62: 28-37. 11. Khullar V, et al. Eur Urol. 2013;63:283–295; 12. Freeman R, et al. Curr Med Res Opin. 2018;34:785–793

Adverse events should be reported. For Ireland, Healthcare professionals are asked to report any suspected adverse reactions via: HPRA Pharmacovigilance, Website: www.hpra.ie or Astellas Pharma Co. Ltd. Tel:+353 1 467 1555, E-mail: irishdrugsafety@astellas.com.

MAT-IE-BET-2026-00005 Sep 2026